Применение оральных антикоагулянтов и антиагрегантов в терапии антифосфолипидного синдрома
Диссертация
Перед началом профилактики тромботических осложнений необходимо обязательное проведение всем пациентам с АФС следующих методов обследования: ЭКГ, ЭХОКГ, МРТ головного мозга, определение уровней аКЛ и аПТ, липидного профиля. Пациентам с ИМ или ОНМК в анамнезе, с вальвуло-патиями, с активностью СКВ более 20 баллов по шкале SLEDAI, высокопозитивным по IgGи IgM-аКЛ или аПТ, больным с низким уровнем… Читать ещё >
Список литературы
- Rosove М.Н., Brewer Р.М.С. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients // Ann. Int. Med. — 1992. -№ 117.-P. 303−308.
- Krnic-Barrie S., O’Connor CIR., Looney S.W. et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of influencing recurrent thrombosis // Arch. Intern. Med. 1997. — № 157. — P. 2101−2108.
- Khamashta M.A., Cuadrado M.J., Mujic F. et al. The management of thrombosis in the antiphospholipid-antibody syndrome // N. Engl. J. Med. 1995. -№ 332.-P. 993−997.
- Linkins L.A., Weitz J.I. New anticoagulants // Semin. Thromb. Hemost. -2003.-№ 29.-P. 619−631.
- Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy // Am. J. Med. 1998. — № 104. -P. 332−338.
- Ansell J., Hirsh J., Poller L. et al. The pharmacology and management of the vitamin К antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy // Chest. 2004. — № 126. — P. 204 — 233.
- Hirsh J., Fuster V., Ansell J., Halperin J. L. American Heart Association/American College of Cardiology Foundation Guide to warfarin therapy // Circulation. 2003. — № 107. — P. 1692 — 1711.
- Лечение оральными антикоагулянтами: Рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов имени А. А. Шмидта Б.А.Кудряшова. — М.: РКИ Соверо пресс, 2002. — 36 с.
- Wessler S., Gitel S.N. Warfarin: from bedside to bench // N. Engl. J. Med. 1984. — № 311. — P. 645−652.
- Zivelin A., Rao L.V., Rapaport S.I. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual ptocoagulant vitamin-K dependent clotting factors // J. Clin. Invest. 1993. — № 92. -P. 2131−2140.
- Patel P., Weitz J., Brooker L.A. et al. Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma // Pediatr. Res. — 1996. № 39. — P. 826−830.
- Furie В., Diuguid C.F., Jacobs M. et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy // Blood. 1990. — № 75. — P. 344−349.
- Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus eiytematosus // Thromb. Diath. Haemorrh. 1959. — № 3. — P. 237 256.
- Amengual O., Atsuni Т., Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies // Arthritis Rheum. 2003. — № 48. -P. 886−895.
- Galli M., Barbui T. Anti-prothrombin antibodies: detection and clinical significance // Blood. 1999. — № 93. — P. 2149−2157.
- Horbach D., van Oort E., Derksen R. et al. The contribution of antiprothrombin antibodies to lupus anticoagulant activity discrimination between functional and non-functional anti-prothrombin antibodies // Thromb.Haemost. -1998.-№ 79.-P. 790−795.
- Moll S., Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants // Ann. Intern. Med. 1997. — № 127. — P. 177−185.
- Derksen R.H.W.M., de Groot Ph.G., Kater L. et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment // Ann. Rheum. Dis. 1993. — № 52. — P. 689−692.
- Ginsberg J.S., Wells P. S., Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism // Blood. 1995. — № 86. — P. 3685−3691.
- Ames P.R.J., Ciampa A., Grandone E. et al. Conventional oral anticoagulation (INR 2−3) effectively prevents rethrombosis in primary antiphospholipid antibody syndrome (abstract) // Lupus. 2002. — № 9. — P. 624.
- Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome // N. Engl. J. Med. 2003. — № 349. — P. 11 331 138.
- Brey R.L., Chapman J., Levine S.R. et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002 // Lupus. 2003. -№ 12.-P. 508−513.
- Brey R.L., Levine S.R. APL and the brain: treatment (abstract) // Lupus. -2002.-№ 9.-P. 559.
- Levine S.R., Brey R.L., Tilley B.C. et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke // JAMA. -2004.-№ 291.-P. 576−584.
- Hughes G.R.V. Trombosis, abortion, cerebral disease and lupus anticoagulant //BMJ. 1983. — № 187.-P. 1088−1089.
- Hughes G.R.V., Harris E.N., Charavi A.E. The anticardiolipin syndrome // J. Rheumatol. 1986. — № 13. — P. 486−489.
- Насонов E.JI. Антифосфолипндный синдром: клиническая и иммунологическая характеристка // Клиническая медицина. 1989. — № 1. — С. 5−13.
- Алекберова З.С., Решетняк Т. М., Кошелева Н. М. и соавт. Антифос-фолипидный синдром при системной красной волчанке: оценка диагностических и классификационных критериев // Клиническая медицина. 1996. — № 6. -С. 39−42.
- Решетняк Т.М. Антифосфолипидный синдром: клиника, диагностика, вопросы патогенеза. Дисс.. д-ра. мед. наук. Москва, 1999. — 324 с.
- Asherson R.A., Baguley Е., Hughes G.R.V. Antiphospholipid syndrom: five years follow-up // Ann. Rheum. Dis. 1991. — № 50. — P. 805−810.
- Wood A. Drug therapy // N. Engl. J. Med. 1994. — № 330. — P. 12 871 293.
- Общие сведения о механизмах гемостаза / З. С. Баркаган // Руководство по гематологии: В 3 т. / Под ред. А. И. Воробьева. М.: Ньюдиамед, 2005. -Т.З.-С. 9−28.
- Palkimas М.Р., Skinner Н.М., Gandhi P.J., Gardner A.J. Polymorphisms induced sensitivity to warfarin: a review of the literature // Journal of Thrombosis and Thrombolysis. -2003. № 15. — P. 205−212.
- Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications // Clin. Pharmacokinet. 2001. — № 40. — P. 587−603.
- Esmon С. T. Molecular events that control the protein С anticoagulant pathway // Thromb. Haemost. 1993. — № 70. — P. 29−35.
- Esmon N L., Carrol R.C., Esmon С. T. Thrombomodulin blocks the ability of thrombin to activate platelets // J. Biol. Chem. 1983. — № 258. — P. 1 223 812 242.
- Esmon С. Т., Esmon N L., Harris K.W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation // J. Biol. Chem. 1982. — № 257. — P. 7944−7947.
- Nesheim M., Wang W., Boffa M. et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis // Thromb. Haemost. -1997. -№ 78. -P. 386−391.
- Overduin M., de Beer T. The pilot thickens: how thrombin modulates blood clotting // Nat. Struct. Biol. 2000. — № 7. — P. 267−269.
- Weitz J.I., Hudoba M., Massel D. et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin 1П but is susceptible to inactivation by antithrombin Ill-independent inhibitors // J. Clin. Invest. 1990. — № 86. — P. 385 391.
- Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor // J.Biol. Chem. 1995. — № 270. -P. 14 477−14 484.
- Le D.T., Weibert R.T., Sevilla B.K. et al. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods // Ann. Intern. Med. 1994. — № 120. — P. 552−558.
- Lind S.E., Callas P.W., Golden E.A. et al. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy // Blood Coagul. Fibrinolysis. 1997. — №. 8. — P. 48−53.
- Kornberg A., Francis C.W., Pellegrini V.D. et al. Comparison of native prothrombin antigen with the prothrombin time for monitoring, oral anticoagulant prophylaxis // Circulation. 1993. — № 88. — P. 454−460.
- Wells P. S., Holbrook A.M., Crowther N.R. et al. Interactions of warfarin with drugs and food // Ann. Intern. Med. 1994. — № 121. — P. 676−683.
- Чуваева A.B., Балоян Г. М., Згцйтман E.B. и соавт. Диета и варфари-нотерапия (случай из практики) // Тромбоз, гемостаз и реология. 2004. — № 1. -С. 73−74.
- Readman A. Implications of cytochrome P450 2C9 polymorfism on warfarin metabolism and dosing // Pharmacotherapy. 2001. — № 21. — P. 235−241.
- Bhasker C.R., Miners J.O., Coulter S. et al. Allelic and functional variability of cytochrome P450 2C9 // Pharmacogenetics. 1997. — № 7. — P. 51−58.
- Lee C.R., Goldstein J.A., Pieper J.A. Cytochrome P450 2C9 polymorfisms: a comprehensive review of the in-vitro and human date // Pharmacogenetics. 2002. — № 12. — P. 251−263.
- Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in cytochrome P450 CYP2C9 withwarfarin dose requirement and risk of bleeding complications // Lancet. 1999. — № 353. — P. 717−719.
- Taube J., Halsall D., Baglin T. Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment // Blood. 2000. — № 96. — P. 1816−1819.
- Higashi M., Veenstra D., Midori Kondo L. et al. Association between CYP2C9 genetic variants and anticoagulation related outcomes during warfarin therapy // JAMA. — 2002. — № 287. — P. 1690−1698.
- Joffe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms // Thromb. Haemost. 2004. — № 91. — P. 1123−1128.
- Bodin L., Verstuyft C., Tregouet D.A. et al. Cytochrome P4502C9 (CYP2C9) and vitamin К epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity // Blood. 2005. — № 106. — P. 135−140.
- Kearon C., Gent M., Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism // N. Engl. J. Med. 1999. — № 340. — P. 901−907.
- Landefeld C.S., Beyth R.J. Anticoagulant related bleeding: clinical epidemiology, prediction // Am. J. Med. — 1993. — № 95. — P. 315−328.
- Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin // Ann. Intern. Med. 1994. — № 120. — P. 897−902.
- Beyth R.J., Quinn L., Landefeld C.S. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial // Ann. Intern. Med, 2000. — № 133. — P. 687−695.
- Levine M.N., Rascobe G., Landefeld S., Kearon C. Hemorrhagic complications of anticoagulant treatment // Chest. -2001. № 119. — P. 108−121.
- McCrae K.R. Antiphospholipid antibody associated thrombosis: a consensus for treatment // Lupus. 1996. — № 5. — P. 560−570.
- Панченко Е.П., Добровольский А. Б. Тромбозы в кардиологии: Ме-ханимы развития и возможности терапии. М.* Спорт и культура, 1999. — 464 с.
- Weiss H.J., Aledort L.M. Impaired platelet/connective-tissue reaction in man after aspirin ingestion // Lancet. 1967. — № 2. — P. 495−497.
- Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs // Nature (New Biol.). 1971. — № 231. — P. 232−235.
- Smith J.H., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets // Nature (New Biol.). 1971. — № 231. — P. 235−237.
- Насонов E.JI. Кардиоваскулярные эффекты нестероидных противовоспалительных препаратов // Научно-практическая ревматология. 2003. № З.-С. 28−31.
- Crofford L.J., Lipsky Р.Е., Brooks P. et al. Basic biology and clinical application of specific cyclogenase-2 inhibitors // Arthrit. Rheum. 2000. — № 43. -P. 3157−3160.
- Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclogenase-2 //N. Engl. J. Med. 2001. — № 345. — P. 433−442.
- Smith W.L. Prostanoid biosynthesis and mechanisms of action // Am. J. Physiol. 1992. — № 263. — P. 181−191.
- Насонов Е.Л., Цветкова E.C., Тов Н.Л. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека // Терапевтический архив. 1998. — № 5. — С. 8−14.
- Кукес В.Г., Остроумова О. Д. Кардиомагнил: новый взгляд на ацетилсалициловую кислоту: Пособие для врачей. М.: Никомед Россия-СНГ, 2003. — 24 с.
- Awtry Е.Н., Loscalzo J. Aspirin // Circulation. 2000. — № 101. -P. 1206−1215.
- Patrono C., Coller В., Dalen J. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects // Chest. — 2001. № 119. — P. 3963.
- Speir E., Yu Z.-X., Ferrans V.J. et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells // Circ. Res. 1998. — № 83. — P. 210−216.
- Weyand C.M., Kaiser M., Yang H. et al. Therapeutic effects of acetyl-salicylic acid in giant cell arteritis // Arthrit. Rheum. 2002. — № 46. — P. 457−466.
- Carreras L.D., Machin S.J., Deman R et al. Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacycline formation// Lancet. 1981. — № 1. — P. 244−246.
- Schorer A.E., Wickham N.W. R., Watson K.V. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation // Brit. J. Haematol. 1989. — №. 71. — P. 399−407.
- Lellouche F., Martinuzzo M., Said P., et al. Imbalance of thromboxane / prostacyclin biosyntesis in patients with lupus anticoagulant // Blood. 1991. — № 78. -P. 2894−2899.
- Forastiero R., Martinuzzo M., Carreras L.O., et al. Anti-f32-glycoprotein I antibodies: association with increased urinary excretion of platelet-derived thromboxane urinary metabolites // Thromb. Haemost. 1998. — № 79. — P. 42−45.
- Ferro D., Basili S., Roccaforte S., et al., Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus // Arthrit. Rheum. 1999. — № 42. — P. 2689−2697.
- Алекберова 3.C., Решетняк T.M., Насонов E.JI. и соавт. Уровни тромбоксана и простациклина у больных системной красной волчанкой с анти-фосфолипидным синдромом //Клиническая медицина. 1994. -№ 6. — С 31−35.
- Alarcon-Segovia D., Boffa М.С., Branch W., et al. Prophylaxis of the antiphopholipid syndrome: a consensus report // Lupus. 2003. — № 12. — P. 499 503.
- Erkan D., Merrill J.T., Yazici Y. et al. High thrombosis rate after fetal loss in APS: effective prophylaxis with aspirin // Arthrit. Rheum. 2001. — № 44. — P. 1466−1467.
- Erkan D., Yazici Y., Peterson M.G. et al. A cross-sectional stady of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome // J. Rheumatol. 2002. — № 41. — P. 924−929.
- Erkan D., Lockshin M.D. How much warfarin is enough in APS related thrombosis? // Thromb. Research. 2004. — 114. — P. 435−442.
- Cervera R., Piette J.-C., Font J. et al. Antiphospholipid Syndrome clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients // Arthrit. Rheum. 2002. — № 46. — P. 1019−1027.
- Brey R.L. Management of the neurological manifestations of APS -what do the trials tell us? // Thromb. Research. 2004. — № 114. — P. 489−499.
- Gatenby P.A., Controversies in the antiphospholipid syndrome and stroke // Thromb. Research. 2004. — № 114. — P. 483−488.
- Derksen R.H.W.M., de Groot P.G., Kappell L.J. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome // Neurology. 2003. -№ 61.-P. 111−114.
- Lockshin M., Tenedios F., Petri M. et al. Cardiac disease in the antiphospholipid syndrome recommendations for treatment. Committee consensus report//Lupus.-2003. № 12.-P. 518−523.
- Решетняк T.M., Мач Э.С., Александрова E.H. и соавт. ТромбоАСС в профилактике сосудистых нарушений при антифосфолипидном синдроме // Клиническая медицина. 1999. — № 10. — Р. 30−35.
- Alarcon-Segovia D., Sahchez-Guerrero.J. Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome // J. Rheumatol.-1989.-№ 16.-P. 1359−1361.
- Derksen R.H.W.M., de Groot P.G., Nieuwenhuis H.K. et al. How to treat women with antiphospholipid antibodies in pregnancy // Ann. Rheum. Dis. — 2001. -№ 60.-P. 1−3.
- Derksen R.H.W.M., Khamashta M.A., Branch D.W. Management of the obstetric antiphospholipid syndrom // Arthrit. Rheum. 2004. — № 50. — P. 10 281 039.
- Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies // BMJ. 1997. — № 314. — P. 253−257.
- Khamashta M.A. Hughes Syndrome: antiphospholipid syndrom. London. Springer-Verlag, 2000. — P. 391−396.
- Wahl D.G., Bounameaux H., de Moerloose Ph. et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or withoutantiphospholipid antibodies. A decision analysis // Arch. Intern. Med. 2000. — № 160.-P. 2042−2048.
- Wajed J., Ahmad Y., Durrington P. N. et al. Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management //Rheumatology. 2004. — № 43. — P. 7−12.
- Каратеев A.E. НПВП-индуцированные гастропатии: Методические рекомендации для врачей ревматологов, гастроэнтерологов, терапевтов. М., 2003. — 8с.
- Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding // BMJ. 1995. — № 310. — P. 827−830.
- Caspi D., Lubart E., Graff E. et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients // Arthrit. Rheum. 2000. — № 43.-P. 103−108.
- Fored C.M., Ejerblad E., Lindblad P. et al. Acetaminophen, aspirin, and chronic renal failure //N. Engl. J. Med. 2001. — № 345. — P. 1801−1808.
- Perneger T.V., Whelton P.K., Klag M.J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs //N. Engl. J. Med. 1994. — № 331. — P. 1675−1679.
- Segal R., Lubart E., Leibovitz A. Et al. Early and late effects of low-dose aspirin on renal function in elderly patients // Am. J. Med. 2003. — № 115.-P. 462−466.
- Curhan G.C., Knight E.L., Rosner B. et al. Lifetime nonnarcotic analgetic use and decline in renal function in women // Arch. Intern. Med. 2004. — № 164.-P. 1519−1524.
- Harmankaya O., Basturk Т., Ozturk Y. et al. Effect of acetylsalicylic acid and dipiridamole in primary membranoproliferative glomerulonephritis tipe I // Int. Urol. Nephrol. 2001. — № 33. — P. 583−587.
- He J., Whelton P.K., Vu В., et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials // JAMA. 1998. — № 280. -P. 1930−1935.
- Pass S.E., Simpson R.W. Discontinuation and reinstitution of medications during the perioperative period // Am. J. Health-Syst. Pharm. 2004. — № 61. -P. 899−912.
- Howard P.A. Aspirin resistance // Ann. Pharmacotherapy. 2002. -№ 36.-P. 1620−1624.
- Chamorro A., Escolar G., Revilla M. et al. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study // J. Neurol. Sci. 1999.-№ 171.-P. 110−114.
- Taylor D.W., Barnett H.J., Haynes R.B. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy (ACE) Trial Collaborators // Lancet. 1999. — № 353. — P. 2179−2184.
- Johnson E.S., Lanes S.F., Wentworth C.E. et al. Ametaregression analysis of the dose response effect of aspirin in stroke // Arch. Intern. Med. 1999. — № 159.-P. 1248−1253.
- Berglund U., Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with instable coronary artery disease // Eur. Heart J. 1991. — № 12. — P. 428−433.
- Kawasaki Т., Ozek Y., Igawa Т., Kambabayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin // Stroke. 2000. -№ 31.-P. 591−595.
- Tselepis A.D., Tsoukatos D., Droudes C. et al. Platelet response to the aggregatory effect of platelet activating factor (PAF) ex vivo in patients with acute myocardial infarction // Eur. J. Clin. Invest. 1991. — № 21. — P. 490−496.
- Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin // N. Engl. J. Med. 2001. — № 345. — P. 1809−1817.
- Cipollone F., Ciabattoni G., Patrignani P. et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina // Circulation. — 2000.-№ 102.-P. 1007−1013.
- Eikelboom J.W., Hirsh J., Weitz J.I. et al. Aspirin resistance and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk of cardiovascular outcomes // Circulation. 2002. — № 105. — P. 1650−1655.
- Hankey G.J., Eikelboom J.W. Aspirin resistance // BMJ. 2004. -№ 328.-P. 477−479.
- Wilson W.A., Gharavi A.E., Koike T. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop // Arthrit. Rheum. 1999. — № 42. — P. 1309−1311.
- Alarcon-Segovia D., Perez-Vazquez M.E., Villa A.R. et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus // Semin. Arthritis Rheum. 1992. — № 21. -P.275−286.
- Asherson R.A., Khamashta M.A., Ordi-Ros J. et al. The «primary» antiphospholipid syndrome: major clinical and serological features // Medicine (Baltimore). 1989. — № 68. — P. 366−374.
- Hochberg M.C. Updating the American College of Reumatology revised criteria for the classification of systemic lupus erythematosus // Arthrit. Rheum. -1997.-№ 40.-P. 1725−1734.
- Насонова В.А. Системная красная волчанка. М.: Медицина, 1972. — 248 с.
- Bombardier С., Gladman D.D., Urowitz М.В. et al. Derivation of the SLEDAI (a disease activity index for lupus patients) // Arthrit. Rheum. 1992. -№ 35.-P. 630−640.
- Gladman D.D., Goldsmith C.H., Urowitz M.B. et al. The Systemic Lupus Erythematosus Collaborating Clinics / American College of Reumatology index for systemic lupus erythematosus international comparison // J. Rheumatol. 2000. -№ 27.-P. 373−376.
- Голубев B.JI., Вейн A.M. Неврологические синдромы: Руководство для врачей. М.: Эйдос Медиа, 2002. — 832 с.
- World Health Organization. International Society of Hypertension Guidelines for management of hypertension. Guidelines Subcommittee // J. Hypertens. 1999. — № 17.-P. 151−183.
- Дедов И.И., Мельниченко Г. А., Фадеев B.B. Эндокринология. М.: Медицина, 2000. — 632 с.
- Brandt J.T., Barna L.K., Triplett D.A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for identification of lupus anticoagulants // Thromb. Haemost. 1995. — № 74. — P. 1597−1603.
- Баркаган 3.C., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза. М.: Ньюдиамед, 2001. — 285 с.
- Патрушев Л.И. Тромбофилические состояния и современные методы их диагностики // Русский медицинский журнал. 1998. — № 6. — С. 181−185.
- Wang S.L., Huang J., Lai M.D., Tsai J.J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese // Pharmacogenetics. — 1995.- № 5. -P. 37−42.
- Sullivan-Klose Т.Н., Ghanayem B.I., Bell D.A. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism // Pharmacogenetics. 1996. — № 6. — P. 341−349.
- Patrushev L.I., Zykova E.S., Kayushin A.L. et al. New DNA diagnostic system for detection of factor V Leiden // Thromb. Res. 1998. — № 92. — P. 251 259.
- Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2002. -312 с.
- Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины: Пер. с англ. М.: МедиаСфера, 2004. — 352 с.
- Эрдес Ш. Некоторые вопросы статистического анализа результатов клинических исследований // Научно-практическая ревматология. 2000. -№ 2. — С. 74−77.
- Villani G., Piepoli М., Villani P., Capucci A. Anticoagulation in atrial fibrillation: what is certain and what is to come // Eur. Heart J. 2003. — № 5. — P. 45−50.
- Папаян Л.П., Князева E.C. Д-димер в клинической практике: Пособие для врачей. М.: ООО Инсайт полиграфик, 2002. — 20 с.
- Hylek E., Go A., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. -№ 349.-P. 1019−1026.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. 2002. — № 324. — P. 71−86.
- Makris M., Watson H.G. The management of coumarin-induced over-coagulation // Br. J. Haematol. 2001. — № 114. — P. 271−280.
- Fihn S.D., McDonell M., Martin D. et al. Risk factors for complications of chronic anticoagulation. A multicenter study warfarin optimized outpatient follow-up study group // Ann. Intern. Med. 1993. — № 118. — P. 511−520.
- Насонов E.JI., Карпов Ю. А., Алекберова З. С. и соавт. Артериальная гипертония и антифосфолипидный синдром // Терапевтический архив. — 1996. -№ 2.-С. 37−40.
- Sangle S.R., D’Cruz D.P., Khamashta М., Hughes G.R.V. Prevalence of hypertension in 600 patients with antiphospholipid syndrome (abstract) // ACR/ARHP Annual Scientific Meeting. 2003. — P. 868.
- Hypertension in primary antiphospholipid syndrome (abstract) / M.A. Bacon, M.L. Bertolaccini, Y. Karim et al. // ACR/ARHP Annual Scientific Meeting. -2003.-P. 870.
- Rosendaal F.R. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis // Thromb. Haemost. 1997. — № 78. — P. 1−6.
- Tsai A.W., Cushman M.3 Rosamond W.D. et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology // Arch. Intern. Med. 2002. — № 162. — P. 1182−1189.
- Rodgers H., Greenaway J., Davis T. et al. Risk factors for first ever stroke in older people in the North East of England. A population — based study // Stroke. — 2004. — № 35. — P. 7−11.
- Meroni P.L., Moia M., Derksen R.H.W.M. et al. Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis // Lupus. 2003. — № 12. — P. 504−507.
- Ward M.M. Premature morbidity from cardiovascular disease in women with systemic lupus erythematosus // Arthrit. Rheum. 1999. — № 42. -P. 338−346.
- Esdale J.M., Abrachamowicz M., Grodzicky T. et al. Traditional Fram-ingham risk factor fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus // Arthrit. Rheum. 2001. — № 44. — P. 2331−2337.
- Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective // Scand.J. Rheum. 1996. — № 25. — P. 191−193.
- Vianna J.L., Khamashta M.A., Ordi-Ros J. et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients // Am. J. Med. 1994. — № 96. — P. 3−9.
- Roman M.J., Shanker B.A., Davis A. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus // N. Engl. J. Med. -2003. № 349. — P. 2399−2406.
- Redondo S., Santos-Gallego C.G., Ganado P. et al. Acetylsalicilic acid inhibits cell proliferation by transforming growth factor beta // Circulation. — 2003. — № 107.-P. 626−629.
- Levin S.R., Brey R.L., Joseph C.L.M. et al. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies // Stroke. 1992. — № 23. — P. 29−32.
- D’Alton J.G., Preston D.N., Bormanis J. et al. Multiple transient ischemic attacks, lupus anticoagulant and verrucous endocarditis // Stroke. 1985. -№ 16.-P. 512−514.
- Young S.M., Fisher M., Sigsbee A., Errichetti A. Cardiogenic brain embolism and anticoagulant // Ann. Neurol. 1989. — № 26. — P. 390−392.
- Barbut D., Borer J.S., Wallerson D. et al. Anticardiolipin antibodies and stroke: possible relation of valvular heart disease and embolic events // Cardiology. -1991.-№ 79.-P. 99−109.
- Pope J.M., Canny C.L.B., Bell D.A. Cerebral ischemic events associated with endocarditis, retinal vascular disease, and anticoagulant // Am. J. Med. — 1991. -№ 90.-P. 299−309.
- Nesher G., Ilany J., Rosenmann D., Abraham A.S. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment // Sem. Ar-thrit. Rheum. 1997. — № 27. — P. 27−35.
- Roubey R.A.S. Mechanisms of autoantibody-mediated thrombosis // Lupus. 1998. -№ 7. -P. 114−119.
- Meroni P.L., Riboldi P. Pathogenic mechanism mediating antiphospholipid syndrome // Curr. Opin. Rheum. 2001. — № 13. — P. 377−382.
- Ziporen L., Goldberg I., Arad M. et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic finding in deformed heart valves // Lupus. 1996. — № 5. — P. 196−205.
- Afek A., Shoenfeld Y., Manor R. Et al. Increased endothelial cell expression of alpha3-betal-integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome // Lupus. 1999. — № 8. — P. 502−507.
- Horbach D.A., van Oort E., Derksen R.H., de Groot P.G. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus // Thromb. Haemost. 1996. — № 76. — P. 916 924.
- Wahl D.G., Guillemin F., de Maistre E. et al. Meta-analysis of the risk of venous thrombosis individuals with antiphospholipid antibodies without autoimmune disease or previous thrombosis // Lupus. 1998. — № 7. — P. 15−22.
- Galli M., Dlott J., Norbis F. et al. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests // Thromb. Haemost. 2000. — № 84. — P. 1012−1016.
- Galli M., Finazzi G., Norbis F. et al. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile // Thromb. Haemost. 1999. — № 81. — P. 695−701.
- Anti-prothrombin antibodies / M. Galli // The antiphospholipid syndrome II: autoimmune thrombosis / Ed. R.A. Asherson, R. Cervera, J. Ch. Piette, Y. Shoenfeld. Elsevier, 2002. — P. 59−69.
- Pasquier E., Amiral J., de Saint Martin L., Mottier D. A cross sectional study of antiphospholipid-protein antibodies in patients with venous thromboembolism // Thromb. Haemost. 2001. — № 86. — P. 538−542.
- Vaarala O., Puurunen M., Manttari M. et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men // Thromb. Haemost. -1996.-№ 75.-P. 456−459.
- Palosuo Т., Virtamo J., Taylor P.R. et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men // Thromb. Haemost. 1997. — № 78. — P. 1178−1182.
- Galli M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk? // Thromb. Research. 2004. — № 114. — P. 597−601.
- Vaarala O., Manttari M., Manninen V. et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men // Circulation. 1995. -№ 91. -P. 23−27.
- Vaarala O. Antiphospholipid antibodies and myocardial infarction // Lupus. 1998. — № 7. — P. 132−134.
- Hamsten A., Norberg R., Bjorkholm M. et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events // Lancet. 1986. — № 1. — P. 113−116.
- Bili A., Moss A J., Francis C.W. et al. Anticardiolipin antibodies and recurrent coronary events. A prospective study of 1150 patients // Circulation. 2000. -№ 102.-P. 1258−1263.
- Sltenes K.E., Smith P., Abedlnoor M. et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke // Lancet. 1992. — № 339. — P. 451−453.
- Phadke K.V., Phillips R.A., Clarke D.T.R. et al. Anticardiolipin antibodies in ischemic heart disease: marker or myth? // Br. Heart J. 1993. — № 69. — P. 391−394.
- Cortellaro M., Boschetti M., Cardillo M., Barbui T. Antiphospholipid antibodies in patients with previous myocardial infarction // Lancet. 1992. — № 339. — P. 929−930.
- Muir K.W., Squire I.B., Alwan W., Lees K.R. Anticardiolipin antibodies in an unselected stroke population // Lancet. 1994. — № 344. — P. 452−456.
- Finazzi G., Brancaccio V., Moia M. et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry // Am. J. Med. 1996. — № 100. — P. 530−536.
- Баркаган З.С. Геморрагические заболевания и синдромы. М.: Медицина, 1988.-528 с.
- Насонов E. J1., Баранов А. А., Шилкина Н. П. Васкулиты и васкуло-патии. Ярославль: Верхняя Волга, 1999. — 616 с.
- Рациональная фармакотерапия ревматических заболеваний: Руководство для практических врачей / В. А. Насонова, Е. Л. Насонов, Р. Т. Алекперов и др. Под ред. В. А. Насоновой, Е. Л. Насонова. М.: Литтерра, 2003. — 507 с.
- Diz-Kucukkaya R., Hacihanefloglu A., Yenerel М et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study // Blood. 2001. — № 98. — P. 1760−1764.
- Bajaj S.P., Rapaport S.I., Fierer D.S. et al. A mechanism for the hypo-prothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome // Blood. 1983. — № 61. — P. 684−692.
- Erkan D., Bateman H., Lockshin M.D. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of 2 cases and review of literature // Lupus. 1999. — № 8. — P. 560−564.
- Edwards M.N., Pierangeli S., Liu X. et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice // Circulation. -1997. № 96. — P. 4380−4384.
- Wallace D.J., Linker-Israeli M., Metzger A.L., Stecher V.J. The prevalence of antimalarial therapy with regard thrombosis, hypercholesterolemia and cytokines in SLE // Lupus. 1993. — № 2. — P. 13−15.
- Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipid, glucose and thrombosis // Lupus. 1996. — № 5. — P. 16−22.
- Насонов Е.Л., Иванова M.M. Антималярийные (аминохинолино-вые) препараты: новые фармакологические свойства и перспективы клинического применения // Клиническая фармакология и терапия. 1998. — № 3. -С. 65−68.
- Espinola R.G., Pierangeli S., Ghara A.E., Harris E.N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies // Thromb. Haemost. 2002. — № 87. — P. 518−522.
- Alarcon-Segovia D., Deleze M., Oria C. et al. Antiphospholipid antibodies and antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients // Medicine. 1989. — № 68. — P. 353−365.
- Out H.J., van Vliet M., de Groot P.G., Derksen R.H. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titer in patients with systemic lupus erythematosus // Ann. Rheum. Dis. 1992. — № 51. — P. 353−357.
- Asherson R.A., Cervera R., Piette J.C. et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients // Medicine. — 1998. -№ 77. -P. 195−207.
- Левшин Н.Ю., Аршинов A.B., Масина И. В., Емануйлов В. И. Влияние пульс-терапии глюкокортикоидами и циклофосфаном на тромбоцитарно-сосудистый гемостаз при системной красной волчанке (абстракт) // Научно-практическая ревматология. 2005. — № 3. — С. 73.
- Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004. — 440 с.
- River G., Khamashta М.А., Hughes G.R.V. Warfarin and azathioprine: a drug interaction does exist // Am. J. Med. 1993. — № 95. — P. 342.
- Аршинов A.B., Масина И. В., Левшин Н. Ю., Дешеулин А. С. Влияние терапии цитостатиками на состояние гемостаза у больных системной красной волчанкой // Тезисы международного конгресса «Тромбоз, гемостаз, патология сосудов». СПб., 2004. — С. 68−69.
- Walker I.D., Greaves М., Preston F.E. Investigation and management of heritable thrombophilia // Br. J. Haemotol. 2001. — № 114. — P. 512−528.
- Bauer К.A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications // Ann. Intern. Med. 2001. — № 135. -P. 367−373.
- Тихонова T.M. Факторы риска тромбозов и состояние гемодинамики при антифосфолипидном синдроме: Дис. .канд-та мед. наук. Москва, 2003.- 174 с.
- Verhoef P., Meleady R., Daly L. et al. Homocysteine, vitamin status and risk of vascular disease // Eur. Heart J. 1999. — № 20. — P. 1234−1244.
- Heinrich J., Balleisen L., Schulte H. et al. Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men // Arterioscler. Thromb. 1994. — № 14. — P. 54−59.
- Svenungsson E., Jensen-Urstad K., Heimburger M. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus // Circulation. 2001. -№ 104.-P. 1887−1893.
- Bruce I.N., Urowitz M.B., Glandman D.D., hallett D.C. Natural history of hyperlipidemia in systemic lupus erythematosus // J. Rheumatol. 1999. — № 26. -P. 2137−2143.
- Garrido J.A., Peromingo J.A.D., Sesma P., Pia G. More about the link between thrombosis and atherosclerosis in autoimmune disease: triglicerides and risk for thrombosis in patients with antiphospholipid antibodies // J. Rheumatol. 1994. -№ 21.-P. 2394.
- Насонов E.JI. патогенетическое и клиническое обоснование применения статинов при системной красной волчанке и антифосфолипидном синдроме // Клиническая фармакология и терапия. — 2004. № 13. — С. 1−8.
- Roubey R.A.S. New approaches to prevention of thrombosis in antiphospholipid syndrome: hopes, trials, and tribulations // Arthrit. Rheum. 2003. -№ 48.-P. 3004−3008.
- Schulman S. Care of receiving long-term anticoagulant therapy // N. Engl. J. Med. 2003. — № 349. — P. 675−683.
- Wittkowsky A.K., Devine E.B. Frequency and causes of overanticoagu-lation and underanticoagulation in patients treated with warfarin // Pharmacotherapy. 2004. — № 24. — P. 1311−1316.
- Ansell J.E. Optimizing the efficacy and safety of oral anticoagulant therapy: high-quality dose management, anticoagulation clinics, and patient self-management // Semin. Vase. Med. 2003. — № 3. — P. 261−269.
- Gurwitz J.H., Avorn J., Ross-Degnan D. et al. Aging and the anticoagulant response to warfarin therapy // Ann. Intern. Med. 1992. — № 116. — P. 901 904.
- James A.H., Britt R.P., Raskino C.L. et al. Factors affecting the maintenance dose of warfarin // J. Clin. Pathol. 1992. — № 45. — P. 704−706.
- Garcia D., Regan S., Crowther M et al. Warfarin maintenance dosing patterns in clinical practice: implication for safer anticoagulation in the elderly population // Chest. 2005. — № 127. — P. 2049−2056.
- Макацария А.Д., Бицадзе В. О. Тромбофилии и противотромботиче-ская терапия в акушерской практике. М.: Триада-Х, 2003. — 904 с.
- Meade T.W., Mellows S., Brozovic M., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study // Lancet. 1986. — № 2. — P. 533−537.